RÉSUMÉ
Despite advances in breast cancer care, breast cancer in young women (BCYW) faces unique challenges, diagnostic delays, and limited awareness in many countries. Here, we discuss the challenges and consequences associated with the delayed diagnosis of BCYW. The consequences of delayed diagnosis in young women - which generally varies among developed, developing, or underdeveloped countries - are severe due to a faster breast tumor growth rate than tumors in older women, also contributing to advanced cancer stages and poorer outcomes. Though there are many underlying reasons for diagnostic delays due to age, the article delves explicitly deep into the diagnostic delay of BCYW, focusing on healthcare providers, potential contributing factors, its consequences, and the urgent need to start minimizing such incidences. The article suggests several strategies to address these issues, including increasing awareness, developing educational programs for healthcare providers to identify signs and symptoms in young women, developing clear diagnostic guidelines, and improving screening strategies.
Sujet(s)
Tumeurs du sein , Femelle , Humains , Sujet âgé , Tumeurs du sein/diagnostic , Tumeurs du sein/anatomopathologie , Retard de diagnostic/prévention et contrôle , Personnel de santé , Dépistage précoce du cancer , Facteurs tempsSujet(s)
Tumeurs du sein , Santé des femmes , Femelle , Humains , Attitude envers la santé , Tumeurs du sein/diagnosticRÉSUMÉ
Introduction: The essential goal of neoadjuvant chemotherapy (NACT) is to downstage the primary tumor making it amenable for breast conservation surgery (BCS). However, since the safety of this surgery is paramount, post-NACT breast conservation rates remain low. As per the recommendation of the 2018 Early Breast Cancer Trialists' Collaborative Group (EBCTCG) overview of long-term post-NACT follow-up, we have devised a protocol for imaging, localization, rad-path analysis, and documentation of radiotherapy techniques to ensure the safety of post-NACT breast conservation. Methods: This is a retrospective cohort of 180 breast cancer patients who received NACT and were operated on by a single surgical oncologist from 2015 to 2020. After selection based on published guidelines, patients were treated with neoadjuvant systemic (chemo or hormone) therapy. In cases where primary tumors responded and reduced to 1-2 cm in size mid-NACT, the residual tumors were localized by clips under ultrasound guidance and calcification was wire localized. All patients were treated using appropriate surgical and oncoplastic techniques where indicated. Negative margins were ensured by intra-operative rad-path analysis. Adjuvant chemotherapy and radiotherapy were given as per protocol. Results: In 81 cases that required mastectomy at presentation, we were able to achieve a 72.8% post-NACT BCS rate with the help of oncoplasty. Overall, 142 of 180 (80%) patients were treated with breast conserving surgery of which 80% (121 of 142) were oncoplasty. Margins were assessed on intra-operative frozen and re-excised in the same setting. No positive margins were reported in final histopath of 142 breast conservation procedures. Post-operative complication rates after breast conservation in the first year were at 17% (24 of 142 including two major complications). Patient reported outcomes were satisfactory with increased satisfaction for breast conservation compared with immediate breast reconstruction. Discussion: Employing oncoplastic breast surgery (OBS) techniques following stringent protocols for accurate localization of the residual tumor, intra-operative rad-path analysis, and adjuvant treatments, we show successful breast conservation in 72.8% of our mastectomy-qualified patients after downstaging by NACT. We also report satisfactory outcomes for post-NACT surgery, patient-reported satisfaction, and survival.
Sujet(s)
Tumeurs du sein , Tumeurs du sein/diagnostic , Femelle , Humains , Pronostic , Récepteur ErbB-2 , Récepteurs à la progestéroneSujet(s)
Tumeurs du sein/traitement médicamenteux , Lapatinib/administration et posologie , Récepteur ErbB-2/analyse , Tumeurs du sein/mortalité , Tumeurs du sein/anatomopathologie , Femelle , Humains , Traitement néoadjuvant , Récepteur ErbB-2/antagonistes et inhibiteurs , Trastuzumab/administration et posologieSujet(s)
Tumeurs du sein , Dimaprit/analogues et dérivés , Études de suivi , Humains , Paclitaxel , Récepteur ErbB-2 , TrastuzumabSujet(s)
Tumeurs du sein/imagerie diagnostique , Tumeurs du sein/anatomopathologie , Noeuds lymphatiques/imagerie diagnostique , Noeuds lymphatiques/anatomopathologie , Essais cliniques comme sujet/économie , Essais cliniques comme sujet/méthodes , Femelle , Humains , Métastase lymphatique , Lymphoscintigraphie/économie , Lymphoscintigraphie/méthodes , Biopsie de noeud lymphatique sentinelle/économie , Biopsie de noeud lymphatique sentinelle/méthodesSujet(s)
Tumeurs du sein , Mastectomie , Aisselle , Traitement médicamenteux adjuvant , Femelle , Humains , Traitement néoadjuvantRÉSUMÉ
OBJECTIVE: To assess late clinical outcomes with image guided intensity modulated radiotherapy (IG- IMRT) in gynecological malignancies. PATIENTS AND METHODS: We have been practicing IG IMRT for gynecological malignancies since January 2009. Here we are presenting our experience with this modern technique at median follow up of 38 months. During whole treatment bladder filling protocol was followed. Both target volumes and critical structures were contoured according to RTOG guidelines. Dose prescribed to clinical target volume (postop bed and nodal volume) was 50.4 Gy in 28 fractions. Cone beam CT (CBCT) scans were taken to quantify the status of target volume and normal structures. RESULTS: 80 patients were evaluated and analyzed who were treated from January 2009 to December 2014. Median age of our patients was 56.5 years. Out of eighty, forty four patients (55%) were of carcinoma endometrium and the rest 36 (45%) were of carcinoma cervix. None of our patients experienced late grade 3 or 4 bladder toxicity. Although late grade 3 and 4 bowel and rectal toxicity was experienced by single patient. 2.5% patients developed local recurrence, 5% patient developed nodal with distant metastases and 6.25% only distant metastases. Three of our patients developed lung cancer as second primary during follow up. 76.2% atients are alive with regular follow up. CONCLUSIONS: Our study concluded that IG IMRT increases patient compliance and reduces long-term side effects in post-operative gynecological malignancies without compromising local-regional control, disease free survival and overall survival.